AMR advisor calls for public utility company to tackle AMR
March 28, 2019Medical Communications, Research and Development AMR, Lord Jim O'Neill, antimicrobial resistance, pharma, public health
Lord Jim O’Neill, an economist and former government advisor on antimicrobial resistance (AMR), has accused the pharmaceutical industry of “spewing …
AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England
March 28, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer
AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …
Gilead accused of ripping off US taxpayers
March 28, 2019Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents
Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …
Japanese court orders public health campaigner to pay ¥3.3 million to anti-vaccine researcher
March 27, 2019Medical Communications, Research and Development HPV, Japan, anti vaxx, anti-vaccine, public health, vaccines
Dr Riko Muranaka, a researcher and journalist who has campaigned against misinformation surrounding vaccines, has been ordered to pay ¥3.3 …
Measles outbreak spurs New York County to ban all unvaccinated children from public spaces
March 27, 2019Research and Development New York, US, pharma, vaccination, vaccines
Rockland County, New York State, is taking serious measures to combat its biggest measles outbreak in decades, making the decision …
Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications
March 27, 2019Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis
AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …
Children with high adherence to ADHD medication methylphenidate at greater risk of being prescribed antidepressants
March 27, 2019Research and Development ADHA, mental health, methylphenidate, mph, psychiatric disorders
Children who were treated with methylphenidate-based medications (i.e. Ritalin) for conditions such as ADHD were at significantly greater risk of …
Novartis’ new MS drug to cost $88,000 a year
March 27, 2019Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis
Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …
Purdue Pharma settle Oklahoma lawsuit for $270 million
March 26, 2019Research and Development Oklahoma, OxyContin, Purdue Pharma, opioid crisis, oxycodone
OxyContin drugmaker Purdue Pharma has agreed to pay nearly $270 million to the state of Oklahoma, in order to settle …
Novo Nordisk’s oral semaglutide outclasses Januvia with new data in type 2 diabetes
March 26, 2019Manufacturing and Production, Research and Development Novo Nordisk, Ozempic, diabetes, pharma, type 2 diabetes
Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the …
Aimmune’s peanut allergy therapy closes in on approval with promising Phase 3 data
March 26, 2019Manufacturing and Production, Research and Development AR101, Aimmune, allergy, pharma
Aimmune Therapeutics is gearing up for regulatory review of its investigational food allergy therapy AR101 following the release of new …
Sackler Trust halts donations in UK
March 26, 2019Manufacturing and Production Sackler Trust, arts, culture, donations, funding, gallery, sackler
The Sackler Trust has announced it is suspending all new donations in the UK amid negative publicity linking the family’s …
Sanofi may airlift flu vaccines into UK after Brexit
March 26, 2019Manufacturing and Production EU, France, Sanofi, UK, brexit, channel tunnel, vaccines
French firm Sanofi would airlift flu vaccines into the UK in the case of a highly disruptive exit from the …
Google accused of profiting from misleading dementia supplement ads
March 26, 2019Manufacturing and Production Alzheimer's, dementia, google, pseudomedicine, search engines, tech
Google has been accused of profiting from false hope after running adverts for unproven dementia treatments which can cost as …
Conducting internal investigations within a pharmaceutical business
March 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Reed Smith, feature, internal investigations, pharma
Though often necessary, internal investigations are seldom smooth or easy. Rosanne Kay, Partner at law firm Reed Smith, outlines a …
Sanofi and Lexicon’s Zynquista denied type 1 diabetes approval by FDA complete response letter
March 25, 2019Sales and Marketing Zynquista. FDA, diabetes, pharma
Sanofi and Lexicon’s Zynquista (sotagliflozin) has hit a hurdle on its way to US approval for the treatment of type …
NICE recommend Takeda’s lymphoma treatment Adcetris
March 25, 2019Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation
Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …
Africa’s legal cannabis market could generate $7.1 billion each year by 2023
March 25, 2019Sales and Marketing Africa, UN, cannabis, medicnial cannabis, prohibition partners
Africa’s legal cannabis market could generate more than $7.1 billion each year by 2023, according to a report from market …
AZ’s diabetes drug Forxiga secures EU approval for adjunctive use in type 1 patients
March 25, 2019Sales and Marketing AstraZeneca, Forxiga, diabetes, pharma
AstraZeneca has revealed that its sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin) has secured approval from the European Commission for …
Advertising Standards Authority tells therapists to stop marketing ‘autism cure’
March 25, 2019Sales and Marketing ASA, CEASE therapy, advertising standards authority, anti-vaccines, autism, vaccines
The Advertising Standards Authority (ASA) has told British therapists to stop marketing a sham ‘cure’ for autism. The regulator told …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
